Abiopharma

🔍 FORMELA JEAN FRANCOIS (Executive)

Company: Korro Bio, Inc. (KRRO)

Report Date: 2026-06-22

Detailed Transactions and Holdings:

• Sold 3,382 shares of Common Stock at $13.95 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 936,252.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 580 shares of Common Stock at $13.95 per share (Direct)
  Date: 2026-06-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 194,075.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 101,579 shares of Common Stock at $14.25 per share (Direct)
  Date: 2026-06-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 834,673.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
• Sold 17,426 shares of Common Stock at $14.25 per share (Direct)
  Date: 2026-06-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 176,649.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 40,679 shares of Common Stock at $14.6 per share (Direct)
  Date: 2026-06-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 793,994.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
• Sold 666 shares of Common Stock at $14.98 per share (Direct)
  Date: 2026-06-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 793,328.00 | transaction_form_type: 4 | Footnotes: F1, F6, F2
• Sold 6,979 shares of Common Stock at $14.6 per share (Direct)
  Date: 2026-06-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 169,670.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 114 shares of Common Stock at $14.98 per share (Direct)
  Date: 2026-06-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 169,556.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3

Footnotes:

• F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2026.
• F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("AVA XI LP") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
• F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (4), (5) and (6).
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.88 inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.97 to $15.10 inclusive.